Journal
EPIGENETICS
Volume 8, Issue 6, Pages 624-634Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/epi.24816
Keywords
DNA methylation; Hedgehog pathway; ZIC1; ZIC4; ovarian cancer
Funding
- National Cancer Institute [U54 CA113001]
- Integrative Cancer Biology Program, Centers for Cancer Systems Biology
- Ovarian Cancer Research Fund [CA85289, PPDIU01.2011]
- Department of Health [DOH101-TD-PB-111-NSC008]
- Div Of Information & Intelligent Systems
- Direct For Computer & Info Scie & Enginr [1218201] Funding Source: National Science Foundation
Ask authors/readers for more resources
Women with advanced stage ovarian cancer (OC) have a five-year survival rate of less than 25%. OC progression is associated with accumulation of epigenetic alterations and aberrant DNA methylation in gene promoters acts as an inactivating hit during OC initiation and progression. Abnormal DNA methylation in OC has been used to predict disease outcome and therapy response. To globally examine DNA methylation in OC, we used next-generation sequencing technology, MethylCap-sequencing, to screen 75 malignant and 26 normal or benign ovarian tissues. Differential DNA methylation regions (DMRs) were identified, and the Kaplan-Meier method and Cox proportional hazard model were used to correlate methylation with clinical endpoints. Functional role of specific genes identified by MethylCap-sequencing was examined in in vitro assays. We identified 577 DMRs that distinguished (p < 0.001) malignant from non-malignant ovarian tissues; of these, 63 DMRs correlated (p < 0.001) with poor progression free survival (PFS). Concordant hypermethylation and corresponding gene silencing of sonic hedgehog pathway members ZIC1 and ZIC4 in OC tumors was confirmed in a panel of OC cell lines, and ZIC1 and ZIC4 repression correlated with increased proliferation, migration and invasion. ZIC1 promoter hypermethylation correlated (p < 0.01) with poor PFS. In summary, we identified functional DNA methylation biomarkers significantly associated with clinical outcome in OC and suggest our comprehensive methylome analysis has significant translational potential for guiding the design of future clinical investigations targeting the OC epigenome. Methylation of ZIC1, a putative tumor suppressor, may be a novel determinant of OC outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available